Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence ADGQpGAKGEpGDAGAKGDAGppGP
Primary information
sequence IDSeq_167
Peptide sequenceADGQPGAKGEPGDAGAKGDAGPPGP
CancerPDF_ID CancerPDF_ID10887, CancerPDF_ID10891, CancerPDF_ID10894,
PMID21805675,21805675,21805675
Protein NameCollagen alpha-1(I) chain,Collagen alpha-1(I) chain,Collagen alpha-1(I) chain
UniprotKB Entry NameCO1A1_HUMAN,CO1A1_HUMAN,CO1A1_HUMAN
FluidUrine,Urine,Urine
M/Z2189.9958,2206.0017,2221.9847
ChargeNA,NA,NA
Mass (in Da)NA,NA,NA
fdrNA,NA,NA
Profiling TechniqueMALDI-TOF,MALDI-TOF,MALDI-TOF
Peptide Identification techniqueMALDI-TOF-MS,MALDI-TOF-MS,MALDI-TOF-MS
Quantification TechniqueNA,NA,NA
Labelled/Label FreeLabel Free,Label Free,Label Free
FDR1,1,1
CancerPDF_ID CancerPDF_ID10887, CancerPDF_ID10891, CancerPDF_ID10894,
p-ValueNA,NA,NA
SoftwareNA,NA,NA
Length25,25,25
Cancer TypeMuscle-invasive bladder cancer,Muscle-invasive bladder cancer,Muscle-invasive bladder cancer
DatabaseSwissProt Database,SwissProt Database,SwissProt Database
ModificationOxidation: 22,"Oxidation: 11, 23","Oxidation: 5, 11, 23"
Number of Patients751 bladder cancer and 127 control,751 bladder cancer and 127 control,751 bladder cancer and 127 control
RegulationDifferentially expressed between cancer vs normal samples,Differentially expressed between cancer vs normal samples,Differentially expressed between cancer vs normal samples
ValidationMann-Whitney tests and areas under receiver-operator characteristic,Mann-Whitney tests and areas under receiver-operator characteristic,Mann-Whitney tests and areas under receiver-operator characteristic
SensitivityNA,NA,NA
SpecificityNA,NA,NA
AccuracyNA,NA,NA
Peptide AtlasNA
IEDB
Primary information
sequence IDSeq_170
Peptide sequenceADGQPGAKGEPGDAGAKGDAGPpGP
CancerPDF_ID CancerPDF_ID3717,
PMID27026199
Protein NameCollagen alpha-1(I) chain
UniprotKB Entry NameCO1A1_HUMAN
FluidUrine
fdr2188.99
Profiling Technique"CE-MS, Micro-TOF-MS"
Peptide Identification techniqueMS-MS
Labelled/Label FreeLabel Free
CancerPDF_ID CancerPDF_ID3717,
p-Valueless than 0.05
SoftwareProteome Discoverer 1.2
Length25
Cancer TypeBladder cancer
DatabaseUniprot Human non-redundant Database
Modificationp:Hydroxy-Proline
Number of Patients 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls)
RegulationDifferentially expressed between recurrence of UBC vs recurrence control
ValidationIndependent Validation
SensitivityFor testing dataset 88%
SpecificityFor testing dataset 51%
AccuracyNA
Peptide AtlasNA
IEDBNA
Primary information
sequence IDSeq_171
Peptide sequenceADGQpGAKGEpGDAGAKGDAGPPGp
CancerPDF_ID CancerPDF_ID3721,
PMID27026199
Protein NameCollagen alpha-1(I) chain
UniprotKB Entry NameCO1A1_HUMAN
FluidUrine
fdr2220.99
Profiling Technique"CE-MS, Micro-TOF-MS"
Peptide Identification techniqueMS-MS
Labelled/Label FreeLabel Free
CancerPDF_ID CancerPDF_ID3721,
p-Valueless than 0.05
SoftwareProteome Discoverer 1.2
Length25
Cancer TypeBladder cancer
DatabaseUniprot Human non-redundant Database
Modificationp:Hydroxy-Proline
Number of Patients 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls)
RegulationDifferentially expressed between recurrence of UBC vs recurrence control
ValidationIndependent Validation
SensitivityFor testing dataset 88%
SpecificityFor testing dataset 51%
AccuracyNA
Peptide AtlasNA
IEDBNA
Primary information
sequence IDSeq_173
Peptide sequenceADGQpGAKGEpGDAGAKGDAGppGP
CancerPDF_ID CancerPDF_ID3723,
PMID27026199
Protein NameCollagen alpha-1(I) chain
UniprotKB Entry NameCO1A1_HUMAN
FluidUrine
fdr2236.98
Profiling Technique"CE-MS, Micro-TOF-MS"
Peptide Identification techniqueMS-MS
Labelled/Label FreeLabel Free
CancerPDF_ID CancerPDF_ID3723,
p-Valueless than 0.05
SoftwareProteome Discoverer 1.2
Length25
Cancer TypeBladder cancer
DatabaseUniprot Human non-redundant Database
Modificationp:Hydroxy-Proline
Number of Patients 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls)
RegulationDifferentially expressed between recurrence of UBC vs recurrence control
ValidationIndependent Validation
SensitivityFor testing dataset 88%
SpecificityFor testing dataset 51%
AccuracyNA
Peptide AtlasNA
IEDBNA